Monopar Therapeutics (MNPR) investor relations material

Executive summary

• Q3 net loss was $6.20M vs. $3.44M YoY; cash, cash equivalents and investments totaled $129.4M at September 30, 2026.

• Priorities include completing the rolling ALXN1840 NDA submission and advancing MNPR-101 imaging and therapeutic programs.

• ALXN1840 met its Phase 3 primary copper-mobilization endpoint; Alexion had ended development after Phase 2 mechanistic results and regulatory discussions.

Financial highlights

• Q3 operating expenses were $7.47M vs. $4.09M YoY, including R&D of $4.44M vs. $2.59M and G&A of $3.03M vs. $1.50M.

• Q3 net loss was $6.20M vs. $3.44M YoY; interest income was $1.27M vs. $0.66M.

• 9M operating expenses were $19.34M vs. $10.55M YoY; net loss was $15.40M vs. $8.52M.

• 9M R&D rose $6.73M, mainly from contractor, consulting and personnel costs; G&A rose $2.06M, primarily from personnel and contractor costs.

Outlook and guidance

• Funds as of October 31, 2026 were expected to support planned operations through at least March 31, 2028, including ALXN1840 regulatory work and radiopharmaceutical development.

• The ALXN1840 rolling NDA submission began July 22, with completion expected within several weeks; FDA filing acceptance and approval remain uncertain.

• R&D and G&A expenses were expected to increase with ALXN1840 pre-commercial activities and ongoing clinical and preclinical programs.

• No product-sales revenue is expected unless a candidate is approved and commercialized, licensed or sold.